No Detail Found!

Association of P53 Overexpression with Hormone Receptor Status and Triple Negative Breast Carcinoma.

Author(s)
Samina Qamar Department of Pathology, King Edward Medical University, Lahore, Pakistan
Muhammad Abbas Khokhar Department of Oncology and Radiotherapy, King Edward Medical University, Lahore, Pakistan
Shahid Farooq Department of Surgery, King Edward Medical University, Lahore, Pakistan
Sobia Ashraf Department of Pathology, King Edward Medical University, Lahore, Pakistan
WaqarA Humayon Department of Oncology and Radiotherapy, King Edward Medical University, Lahore, Pakistan
Abdul Rehman Department of Pathology, King Edward Medical University, Lahore, Pakistan
Abstract
Objective: To determine association of p53 overexpression with hormone receptor status in breast carcinoma. Study Design: Descriptive cross-sectional study. Place and Duration of Study: Department of Pathology in collaboration with Department of Oncology, King Edward Medical University, Lahore, from January 2017 to January 2018. Methodology: All adult female patients coming to Department of Oncology with reports of breast cancer biopsy and receptor status were included. Their age, type of surgery, grade of cancer, stage of cancer, and hormone receptor status were noted from records. P53 immunomarker was applied on tumor containing tissue blocks. Pearson Chi-square test was run for strength of association between the variables using SPSS V. 22. Results: Mean age of 91 patients at diagnosis was 48 years ±12.49. Fifty-five (60.4%) patients had ER positive tumors, 36 (39.6%) were ER negative, 53 (58.2%) had PR positive status, and 38 (41.8%) were negative. Same number was seen in HER2 neu staining. Out of 91 cases, 31 (34.1%) were p53 positive and 60 (65.9%) were negative. Out of 55 (60.4%) ER positive cases, 11 (12.1%) were positive for p53 and 44 (48.4%) were p53 negative (p<0.001). PR positive cases (53/58.2%) showed p53 positivity in 7 (7.7%) and negativity in 46 (50.5%) cases (p< 0.001). HER2 positive cases were positive for p53 stain in 8 (8.8%) and negative in 45 (49.5%) cases (p<0.001). Fifteen (16.48%) biopsies were negative for all three hormone receptors. P53 was positive in all of these hormone receptor negative tumors (15/15, 100%), although 9 (60%) showed strong positivity and 6 (40%) exhibited weak staining intensity of p53. Conclusion: P53 overexpression is less frequent in hormone receptor positive breast cancers. However, hormone receptor negative (triple negative) tumors overwhelmingly overexpress p53 protein in tumor cells. P53, detected either immunohistochemically or serologically, can serve to predict poor prognosis and survival in breast cancer patients, unless newer anti-p53 treatments are introduced in Pakistan.
Publication Details
Page(s) 164-167
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 29, Issue: 2, Year: 2019

Request the full text from PASTIC

References
2012.,Cancer Facts and Figures 2012. Atlanta: American Cancer Society -
JemalA,BrayF,CenterMM,FerlayJ,WardE,FormanD, 2011.,CA Cancer J Clin 61 69 -90
BellDW, 2010.Our changing view of the genomic landscape of cancer,J Pathol 220 231 -43
WoodLD,ParsonsDW,JonesS,LinJ,SjöblomT,LearyRJ, 2007.The genomic landscapes of human breast and colorectal cancers,Science 318 1108 -13
SajidMT,AhmedM,AzharM,MustafaQU,ShukrI,AhmedM, 2014.Age-related frequency of triple negative breast cancer in women,J Coll Physicians Surg Pak 24 400 -3
HirshfieldKM,RebbeckTR,LevineAJ, 2010.Germline mutations and polymorphisms in the origins of cancers in women,J Oncol 297671 -
GiacomazziJ,SelistreSG,RossiC,AlemarB,Santos-SilvaP,PereiraFS, 2013.Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil,Cancer 119 4341 -9
McGowanEM,LinY,Hatoum D, 2018.Good guy or bad guy? The duality of wild-Type p53 in hormone-dependent breast cancer origin, treatment, and recurrence,Cancers E172 -
FinettiP,GuilleA,AdelaideJ,BirnbaumD,ChaffanetM,BertucciF., 2014.ESPL1 is a candidate oncogene of luminal B breast cancers,Breast Cancer Res Treat 147 51 -9
2012.Comprehensive molecular portraits of human breast tumours,Nature 490 61 -70
SaeedM,MahmoudN,SugimotoY,EfferthT,Abdel-Aziz H, 2018.Molecular determinants of sensitivity or resistance of cancer cells toward sanguinarine,Front Pharmacol 9 136 -
BrewerHR,JonesME,SchoemakerMJ,AshworthA,SwerdlowAJ, 2017.Family history and risk of breast cancer: an analysis accounting for family structure,Breast Cancer Res Treat 165 193 -200
Livaudais-TomanJ,KarlinerLS,TiceJA,KerlikowskeK,GregorichS,Pérez-StableEJ, 2015.Impact of a primary care based intervention on breast cancer knowledge, risk perception and concern: A randomized, controlled trial,Breast 24 758 -66
SeneviratneS,CampbellI,ScottN,ShirleyR,LawrensonR, 2015.Impact of mammographic screening on ethnic and socioeconomic inequities in breast cancer stage at diagnosis and survival in New Zealand: A cohort study,BMC Public Health 15 46 -
MudvariP,OhshiroK,NairV,HorvathA,KumarR, 2013.Genomic insights into triple-negative and HER2-positive breast cancers using isogenic model systems,PLoS One 8 e74993 -
Darb-EsfahaniS,DenkertC,StenzingerA,SalatC,SinnB,SchemC, 2016.Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy,Oncotarget 7 67686 -98
QinJJ,WangW,ZhangR., 2017.Experimental therapy of advanced breast cancer: Targeting NFAT1-MDM2-p53 pathway,Prog Mol Biol Transl Sci 151 195 -216
YuanY,KosFJ,HeTF,YinHH,LiM,HardwickN, 2017.Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab,Oncoimmunology 6 e1363138 -
SynnottNC,BauerMR,MaddenS,MurrayA,KlingerR,O'Donovan N, 2018.Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007,Cancer Lett 414 99 -106
AhnKJ,ParkJ,ChoiY., 2017.Lymphovascular invasion as a negative prognostic factor for triple-negative breast cancer after surgery,Radiat Oncol J 35 332 -9
SaunusJM,SmartCE,KutasovicJR,JohnstonRL,Kalita-de CroftP,MirandaM, 2018.Multidimensional phenotyping of breast cancer cell lines to guide preclinical research,Breast Cancer Res Treat 167 289 -301
JinJ,ZhangW,JiW,YangF,GuanX, 2017.Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy,Cancer Biol Ther 18 369 -78
Lolas HamamehS,RenbaumP,KamalL,DweikD,SalahatM,JaraysaT, 2017.Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53,Int J Cancer 141 750 -6
BaloghGA,MailoD,NardiH,CorteMM,VincentE,BaruttaE, 2010.Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients,Exp Ther Med 1 357 -61
SadighiS,ZokaasadiM,KasaeianA,MaghsudiS,JahanzadI, 2017.The effect of immunohistochemically detected p53 accumulation in prognosis of breast cancer; A retrospective survey of outcome,PLoS One 12 e0182444 -
0

Citations

0

Downloads

130

Views